All In Biotech

Drug Trial Radar · NCT05060705

"Efesovir" (FS-1) for COVID-19, Phase 2

Randomized Controlled Open Study of Safety and Preliminary Efficiency of the Drug "Efesovir" (Oral Solution) for Coronavirus Infection (COVID-19)

Last checked: Nov 19, 2026Latest source record: Apr 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

62

Planned (sponsor's estimate)

Start

Dec 2025

Primary completion

Apr 2026

Study completion Nov 2026

Sponsor

Sponsor type
Industry
First posted
Sep 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 59 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study of the efficacy and safety of the new drug "Efesovir" in comparison with the drug "Remdesivir" in the treatment of patients hospitalized with COVID-19. The hypothesis of clinical study is the clinical efficacy of new drug "Efesovir" is 10% to 30% higher than of "Remdesivir".

Conditions

  • Covid19

Interventions

  • EfesovirDrug

    Antiviral therapy of COVID19 with Efesovir oral solution in dose 0.125 ml / kg two times per day. Duration of treatment is 5 - 10 days, depending on the severity of the disease.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Response RateTime frame: 21 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Semey Medical University

    Semey, East Kazakhstan, Kazakhstan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.